Rakesh Sharma, MD
Critical Care Medicine · Ronkonkoma, NYNPI 1508942574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,232 and has fallen 50.5% since, to $610 in 2025. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$782
- AbbVie$704
- Johnson & Johnson$610
- Boston Scientific$490
- Shionogi Inc$457
- Pfizer$442
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,80799%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 44 | $782 |
| AbbVie | 34 | $704 |
| Johnson & Johnson | 23 | $610 |
| Boston Scientific | 4 | $490 |
| Shionogi Inc | 13 | $457 |
| Pfizer | 23 | $442 |
| Sanofi | 3 | $371 |
| AstraZeneca | 9 | $369 |
| Novartis | 6 | $174 |
| La Jolla Pharmaceutical Company | 3 | $167 |
| Melinta Therapeutics, LLC | 6 | $162 |
| Chiesi USA, Inc. | 3 | $158 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $117 |
| Novo Nordisk | 5 | $109 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Exact Sciences | 3 | $80 |
| Amarin Pharma, Inc. | 4 | $79 |
| Lilly USA, LLC | 4 | $75 |
| Abbott | 1 | $73 |
| Idorsia Pharmaceuticals US Inc | 3 | $68 |
| Cumberland Pharmaceuticals, Inc. | 3 | $48 |
| Shield Therapeutics Inc | 1 | $26 |
| Gilead | 1 | $25 |
| GSK | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,887 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 73 | $79,530 |
| EliquisApixaban | 18 | $20,188 |
| FarxigaDapagliflozin Propanediol | 19 | $16,830 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $14,372 |
| XareltoRivaroxaban | 11 | $12,107 |
| Atorvastatin Calcium | 357 | $2,880 |
| Risedronate Sodium | 22 | $2,486 |
| Valsartan | 96 | $1,738 |
| Metoprolol Succinate | 144 | $1,712 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 28 | $1,493 |
| Levothyroxine Sodium | 134 | $1,370 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,368 |
| SynthroidLevothyroxine Sodium | 34 | $1,208 |
| Pantoprazole Sodium | 54 | $1,021 |
| Celecoxib | 16 | $991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $782 | $79,53073 claims |
| PfizerEliquis | $442 | $20,18818 claims |
| AstraZenecaFarxiga | $369 | $16,83019 claims |
| Johnson & JohnsonXarelto | $610 | $12,10711 claims |
| AbbVieSynthroid | $704 | $1,20834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Ronkonkoma
- Joshua RosenbergBrooklyn$881K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Boris ShkolnikAlbany$209K
- Paul StrachanMelville$169K
- Anna PodolanczukNew York$116K
- Joanne HessneyRochester$76K
- Jan BakkerNew York$49K
- Hugh CassiereManhasset$49K
- Robert SladenNew York$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.